1. Home
  2. SOUN vs GRFS Comparison

SOUN vs GRFS Comparison

Compare SOUN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SoundHound AI Inc

SOUN

SoundHound AI Inc

HOLD

Current Price

$10.93

Market Cap

5.4B

Sector

Technology

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.02

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOUN
GRFS
Founded
2005
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.0B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
SOUN
GRFS
Price
$10.93
$9.02
Analyst Decision
Buy
Hold
Analyst Count
8
2
Target Price
$16.14
$10.15
AVG Volume (30 Days)
20.8M
551.2K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
1.58%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
$148,404,000.00
$8,821,017,248.00
Revenue This Year
$103.22
$5.36
Revenue Next Year
$37.98
$5.15
P/E Ratio
N/A
$17.99
Revenue Growth
120.52
7.31
52 Week Low
$6.52
$6.19
52 Week High
$24.98
$11.14

Technical Indicators

Market Signals
Indicator
SOUN
GRFS
Relative Strength Index (RSI) 36.28 53.16
Support Level $10.81 $8.69
Resistance Level $11.53 $9.22
Average True Range (ATR) 0.56 0.18
MACD 0.07 0.03
Stochastic Oscillator 13.62 64.15

Price Performance

Historical Comparison
SOUN
GRFS

About SOUN SoundHound AI Inc

SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: